MarketBeat Week in Review – 05/18 - 05/22 Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities The healthcare sector outperformed the rest of the market over the past week.
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.
Pediatrics Medicine Market Size, Industry Report By 2035 The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts
3 Market-Beating Stocks with Exciting Potential Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Could Viking Therapeutics Be the Next Eli Lilly? Demand for weight loss drugs may fuel growth for more than one player.
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.
Best Weight Loss Drug Stocks to Buy in 2026 If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.
Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (
NYSE:ELAN ) and its peers. The pha...
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.
Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.
Eli Lilly Stock: Next Stop $2,000? The company is riding an incredible tailwind.
Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.
Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
Is Kailera Therapeutics a Buy After Its Sizzling IPO? There's a new challenger to the more established players in the weight-loss drug space.
Buy, Sell, or Hold Novo Nordisk at $46? Can Novo Nordisk thrive under intense competitive pressures?
My Top 3 Healthcare Stocks for May 2026 Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.
